Bank Of New York Mellon Corp Lumos Pharma, Inc. Transaction History

Bank Of New York Mellon Corp

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.05 - $9.52 $36,166 - $112,888	11,858 New	11,858 $42,000
Q2 2022 Aug 15, 2022	BUY	$6.68 - $9.39 $6 - $9	1 Added 0.01%	11,858 $91,000
Q3 2021 Nov 12, 2021	SELL	$7.36 - $11.36 $30,205 - $46,621	-4,104 Reduced 25.71%	11,857 $112,000
Q2 2021 Aug 11, 2021	SELL	$9.75 - $13.44 $7,293 - $10,053	-748 Reduced 4.48%	15,961 $0
Q1 2021 May 13, 2021	SELL	$11.58 - $31.11 $9,078 - $24,390	-784 Reduced 4.48%	16,709 $0
Q4 2020 Feb 09, 2021	BUY	$13.61 - $35.91 $238,079 - $628,173	17,493 New	17,493 $0

2.2M

Ticker LUMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,396,070
Market Cap $36.4M
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.